NCT00072176View on ClinicalTrials.gov

Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

May 31, 2009

Study Completion Date

August 31, 2009

Conditions
Endometrial AdenocarcinomaEndometrial Adenosquamous Cell CarcinomaEndometrial Clear Cell CarcinomaEndometrial Papillary Serous CarcinomaRecurrent Endometrial CarcinomaStage IIIA Endometrial CarcinomaStage IIIB Endometrial CarcinomaStage IIIC Endometrial CarcinomaStage IVA Endometrial CarcinomaStage IVB Endometrial Carcinoma
Interventions
DRUG

temsirolimus

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

K7L 3N6

National Cancer Institute of Canada Clinical Trials Group, Kingston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00072176 - Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer | Biotech Hunter | Biotech Hunter